by Margarida Maia, PhD | Nov 13, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend survival for people with malignant gliomas, the developer announced. Gliomas are a group of tumors that form...
by Marisa Wexler, MS | Nov 12, 2025 | Myeloma News
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data from a small clinical trial show. Results from the study were discussed earlier this...
by Margarida Maia, PhD | Nov 12, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase) for adults with high-risk smoldering multiple myeloma, making it the first and only approved treatment for this slow-growing type of multiple myeloma. People with...
by Steve Bryson, PhD | Nov 10, 2025 | Myeloma News
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with hard-to-treat large B-cell lymphoma (LBCL). That’s according to data from the ongoing Phase 1 ANTLER clinical...
by MM360 Staff | Nov 8, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Nov 7, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to daraxonrasib, an oral therapy being developed by Revolution Medicines to treat pancreatic cancer. The FDA gives this designation to experimental medicines designed to treat conditions...
